Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
Lucas Hendrik Overeem, Andreas Peikert, Maxi Dana Hofacker, et al.
Cephalalgia (2021) Vol. 42, Iss. 4-5, pp. 291-301
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 244
CGRP-targeted medication in chronic migraine - systematic review
Renato Oliveira, Raquel Gil‐Gouveia, Francesca Puledda
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 18
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
Hauke Basedau, Lisa-Marie Sturm, Jan Mehnert, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 43
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 38
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
Bianca Raffaelli, Mira Pauline Fitzek, Lucas Hendrik Overeem, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 38
Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy
Mi Ji Lee, Mohammad Al‐Mahdi Al‐Karagholi, Uwe Reuter
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 28
Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
Andreas Straube, Gregor Broessner, Charly Gaul, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 26
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study
Luigi Francesco Iannone, Andrea Burgalassi, Giulia Vigani, et al.
Cephalalgia (2023) Vol. 43, Iss. 4
Open Access | Times Cited: 25
Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 24
International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
Francesca Puledda, Simona Sacco, Hans‐Christoph Diener, et al.
Cephalalgia (2024) Vol. 44, Iss. 9
Closed Access | Times Cited: 13
Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab
Jamie Talbot, Rebecca Stuckey, Natasha Wood, et al.
European Journal of Hospital Pharmacy (2024), pp. ejhpharm-003779
Closed Access | Times Cited: 11
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 1, pp. 57-64
Open Access | Times Cited: 10
Switching CGRP(r) MoAbs in migraine: what evidence?
William Wells-Gatnik, Paolo Martelletti
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 327-333
Closed Access | Times Cited: 9
Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review
Giorgio Dalla Volta, Antonio Munafò, Andrea Burgalassi, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access | Times Cited: 1
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 33
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
Fred Cohen, Hsiangkuo Yuan, Stephen D. Silberstein
BioDrugs (2022) Vol. 36, Iss. 3, pp. 341-358
Open Access | Times Cited: 29
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
Giorgio Lambru, Valeria Caponnetto, Bethany Hill, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 5, pp. 1284-1293
Open Access | Times Cited: 17
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies – insights from the German NeuroTransData registry
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
Fred Cohen, Hsiangkuo Yuan, Ellen Michelle Gibson DePoy, et al.
Neurotherapeutics (2022) Vol. 19, Iss. 3, pp. 922-930
Open Access | Times Cited: 24
An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
Katharina Kaltseis, Vera Filippi, Florian Frank, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Journal of Neurology (2023) Vol. 270, Iss. 11, pp. 5436-5448
Closed Access | Times Cited: 13
Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing
Keiko Ihara, Seiya Ohtani, Narumi Watanabe, et al.
Journal of the Neurological Sciences (2023) Vol. 453, pp. 120811-120811
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top